1. Home
  2. CQP vs INSM Comparison

CQP vs INSM Comparison

Compare CQP & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cheniere Energy Partners LP

CQP

Cheniere Energy Partners LP

HOLD

Current Price

$66.59

Market Cap

34.0B

Sector

Utilities

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$133.66

Market Cap

30.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CQP
INSM
Founded
2003
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.0B
30.1B
IPO Year
2006
2000

Fundamental Metrics

Financial Performance
Metric
CQP
INSM
Price
$66.59
$133.66
Analyst Decision
Sell
Strong Buy
Analyst Count
7
24
Target Price
$60.43
$201.17
AVG Volume (30 Days)
72.3K
1.6M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
5.05%
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
$10,758,000,000.00
N/A
Revenue This Year
$6.35
$182.31
Revenue Next Year
$1.27
$65.19
P/E Ratio
$956.64
N/A
Revenue Growth
23.60
N/A
52 Week Low
$49.53
$63.81
52 Week High
$70.64
$212.75

Technical Indicators

Market Signals
Indicator
CQP
INSM
Relative Strength Index (RSI) 61.68 35.20
Support Level $51.48 $101.55
Resistance Level $70.64 $166.81
Average True Range (ATR) 1.77 4.58
MACD 0.48 -1.41
Stochastic Oscillator 91.21 5.45

Price Performance

Historical Comparison
CQP
INSM

About CQP Cheniere Energy Partners LP

Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The profit generated through those activities is split with parent and operator Cheniere Energy.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: